Ovarian Cancer Continues to Challenge Researchers - Multinational Clinical Trial Underway
According to the American Cancer Society, besides than 22,000 cases of ovarian cancer testament be diagnosed this year, and 15,000 women will die from it. Extended popular in women over 55, there is approximately a one in 69 chance that a woman will business agreement ovarian cancer during her lifetime. Ovarian cancer remains the fifth meaningful justification of cancer deaths among women, and though it is a survivable disease, early detection is vital.
If detected and treated before it spreads preceding the ovaries, 93 percent of women will aware longer than five years. Unfortunately, peerless about 20 percent of the cases are caught before this crucial stage. Fewer than half of women diagnosed with ovarian cancer will survive beyond those five years.
Ovarian cancer often becomes resistant to guideline chemotherapy drugs, which is avowed as "chemoresistance." Chemoresistance makes it gargantuan to successfully carry on and treat ovarian cancer.
A Proactive Advent In relation to Detection
Although ovarian cancer was once coined "the silent killer," today, increased erudition regarding what symptoms to study away for has false it easier for women to detect the cancer in its earliest stages.
According to the Ovarian Cancer Civic Alliance (OCNA), some symptoms crop up even aggrandized frequently in women with ovarian cancer than other women. These symptoms carry bloating, pelvic or abdominal pain, occupation eating or enjoyment adequate quickly, and urinary problems such as exorbitant urgency or frequency.
OCNA encourages women to gape a doctor, preferably a gynecologist, whether they evidence these symptoms nearly diurnal for augmented than a rare weeks or simply sensation abnormal. Women with family histories that combine cancer should be mainly alert to these types of changes in their bodies. "Better unharmed than sorry" is the idea, and doctors will administer pelvic exams, blood tests and transvaginal ultrasounds to gaze for ovarian cancer.
Once diagnosed, treatments vary widely. Depending on what page the cancer is in, treatments can cover surgery, chemotherapy, radiation therapy or investigational treatments in clinical trials. Phenoxodiol, one investigational (experimental) narcotic researchers are studying, is currently commencement Sheet III of the clinical check process. Phenoxodiol, which has designated "Fast Track" status by the U.S. Nourishment and Drug Administration, is believed to guidance chemotherapy drugs, such as carboplatin, bump off chemoresistant cancer cells by removing factors in the cells that block the killing enterprise of chemotherapy. In laboratory studies, phenoxodiol has demonstrated that cancer cells pretreated with phenoxodiol were killed with lower doses of chemotherapy drugs. Importantly, phenoxodiol has been shown not to adversely change accustomed cells in animal and laboratory testing.
A clinical research called "OVATURE," for OVArian Tumour REsponse, is underway to evaluate the safety and effectiveness of phenoxodiol. The trial, which aims to levy 470 patients, is duration conducted at clinical sites in the U.S., Europe and Australia. Researchers dependence that when used in conjunction with chemotherapy (carboplatin), phenoxodiol will battle the cancer exceeding than the chemotherapy can on its own.
In 2007, the Governmental Institutes of Health will invest $106 million in ovarian cancer research. Even in spite of continuous advances in medicine, ovarian and other cancers extreme burdensome to detect and treat. It remains substantial for women to be alert to changes in their bodies and perpetuate a willingness to hire course when something doesn't air right. While feasibly ovarian cancer can no longer be called a "silent killer," it is all the more a close one. Increased awareness and bounteous probation are keys to helping women clash this lethal disease.
For more information on the OVATURE trial, visit http://www.OVATUREtrial.com
Source: http://ezinearticles.com/
Added: February 23, 2008
Cancer Researchers Should Widen Genetic Focus, Studies Suggest - Bloomberg
U.S. Hospitals flunk colon cancer exam - Los Angeles Times
Court 'end of road' for cancer man - The Press Association
BBC News Court 'end of road' for cancer man The Press Association - A High Court bid to get a West Sussex man a cancer drug is an "end of the road" attempt, his lawyer has said. Colin Ross, 55, of Horsham, has cancer of the ... Cancer drug battle goes to court High Court Battle For Cancer Drugs Postcode lottery fight for cancer sufferer -